Vasculitis & polymyalgia rheumatica
Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case–control study
Authors' conclusion
VEXAS- and CMML-PAN are distinct clinical entities with poorer prognosis and unique therapeutic challenges.
Study context
- Population
- Patients diagnosed with primary polyarteritis nodosa (PAN), VEXAS-PAN or CMML-PAN
- Participants
- 23 secondary PAN cases
- Exposure
- VEXAS-PAN and CMML-PAN vs primary PAN
- VEXAS-PANn = 12
- CMML-PANn = 11
- Outcome
- Remission and relapse vs primary PAN
Methodological detailsmulticentre, matched 1:3 by age and gender
- Multicentre
- Matched 1:3 by age and gender
Main finding
As reported in the abstract
Each group vs primary PANAdjusted odds ratio (remission) (95% CI)
VEXAS-PAN
0.15(0.02–1.00)
CMML-PAN
0.12(0.02–0.73)
- VEXAS-PAN
- aHR (relapse) 3.24; P = 0.043
- CMML-PAN
- aHR (relapse) 2.23; P = 0.145
Observational data: associations, not effects.
Further findings
Age at PAN onset
Mortality
| Outcome | VEXAS-PAN | CMML-PAN | Primary PAN |
|---|---|---|---|
| Clinical manifestations in VEXAS-PAN (higher than primary PAN) | |||
| Skin manifestations | 100% | — not stated in the abstract | — not stated in the abstract |
| Orchitis | 67% | — not stated in the abstract | — not stated in the abstract |
| Ocular manifestations | 58% | — not stated in the abstract | — not stated in the abstract |
— not stated in the abstract
- Age at PAN onset — Difference across groups
- P < 0.01
Clinical manifestations in VEXAS-PAN (higher than primary PAN)
- Clinical features of CMML-PAN closely resembled those of primary PAN
Original publication
Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case–control study. Rheumatology (Oxford). Published 23 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →